Combined Effects of Tamoxifen and a Chimeric Humanized Single Chain Antibody against the Type I IGF Receptor on Breast Tumor Growth in vivo

Hormone and Metabolic Research

Volumn 35, Issue 11-12, 2003, Pages 836-842

  Ye, J J ^a   Liang, S J ^a   Guo, N ^a   Li, S L ^a   Wu, A M ^a   Giannini, S ^a,e   Sachdev, D ^b   Yee, D ^b   Brunner N ^c   Ikle, D ^a   Fujita Yamaguchi, Y ^a,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c FINSEN LABORATORY   (Denmark)

^d TOKAI UNIVERSITY   (Japan)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Breast Tumor Growth; IGF; Inhibition; Recombinant Antibody; Single Chain Antibody; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; RECOMBINANT ANTIBODY; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN RECEPTOR; TAMOXIFEN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CANCER INHIBITION; CHIMERA; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; THERAPY; TUMOR GROWTH; TUMOR MODEL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

MINK CELL FOCUS-FORMING VIRUS; MUS MUSCULUS;

EID: 0346725863     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814145     Document Type: Article

References (29)

1. Daughaday WH. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127: 1-4
2. Casella SJ, Han VK, D'Ercole AJ, Svoboda ME, van Wyk JJ. Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites. J Biol Chem 1986; 261: 9268-9273
3. Osborne CK, Coronado EB, Kitten LJ, Arteaga CL, Fuqua SA, Ramasharma K, Marshall M, Li CH. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 1989; 3: 1701-1709
4. Sakano K, Enjoh T, Numata F, Fujiwara H, Marumoto Y, Higashihashi N, Sato Y, Perdue JF, Fujita-Yamaguchi Y. The design, expression, and characterization of human insulin-like growth factor II mutants specific for either the IGF-II/cation independent mannose 6-phosphate receptor or IGF-I receptor. J Biol Chem 1992; 266: 20 626-20 635
5. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53: 3736-3740
6. Resnik JL, Reichar DB, Huey K, Webster NJ, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58: 1159-1164
7. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57: 2687-2693
8. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999; 56: 1-10
9. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989; 49: 6237-6241
10. Arteaga CL, Kitten L-J, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84: 1418-1423
11. Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995; 136: 4298-4303
12. Li S-L, Liang S-J, Guo N, Wu AM, Fujita-Yamaguchi Y. Single chain antibodies against human insulin-like growth factor-I receptor: Expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000; 49: 243-252
13. Li S-L, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun 1993; 196: 92-98
14. Sachdev D, Li S-L, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63: 627-635
15. Brünner N, Bastert GB, Poulsen HS, Spang-Thomsen M, Vindelov L, Nielsen A, Tommerup N, Elling F. Characterization of the T61 human breast carcinoma established in nude mice. Eur J Cancer Clin Oncol 1985; 21: 833-843
16. Fichera E, Liang S-J, Xu Z-D, Guo N, Mineo R, Fujita-Yamaguchi Y. A quantitative reverse transcription and polymerase chain reaction assay reveals increased expression of human insulin-like growth factor-II mRNA in some cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 2000; 10: 61-70
17. Li S-L, Goko H, Xu Z-D, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S, Fujita-Yamaguchi Y. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998; 291: 469-479
18. Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A, Lippman M, Rosen N. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 1988; 48: 6691-6696
19. Brünner N, Yee D, Kern G, Spang-Thomsen M, Lippman ME, Cullen KJ. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 1993; 29A: 562-569
20. Brünner N, Spang-Thomsen M, Cullen KJ. The T61 human breast cancer xenograft: An experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 1997; 39: 87-92
21. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles T-M, Rayston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274
22. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445
23. Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-1, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998; 17: 9994-10 003
24. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor downregulation in tumor cells. Mol Cancer Therapeutics 2002; 1: 1348-1353
25. Furlanetto RW. Receptor-mediated endocytosis and lysosomal processing of insulin-like growth factor I by mitogenically responsive cells. Endocrinology 1988; 122: 2044-2053
26. Hsu D, Knudson PE, Zapf A, Rodband GC, Olefsky JM. NPXY motif in the insulin-like growth factor receptor is required for efficient ligand-mediated receptor internalization and biological signaling. Endocrinology 1994; 134: 744-750
27. Zapf A, Hsu D, Olefsky JM. Comparison of the intracellular itineraries of insulin-like growth factor I and insulin and their receptors in Rat-1 fibroblasts. Endocrinology 1994; 134: 2445-2452
28. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997; 57: 2606-2610
29. Kanter-Lewensohn L, Girnita L, Girnita A, Dricu A, Olsson G, Leech L, Nilsson G, Hilding A, Wejde J, Brismar K, Larsson O. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (1GF-1) pathway. Mol Cell Endocrinol 2000; 156: 131-137